New Targanta Appoints Garen Bohlin to Board of Directors
Targanta Study Shows Oritavancin Treatment Effective
in a Mouse Model of Anthrax
Targanta Reports Improved Ability of Oritavancin To Stop
Bacteria Growth In Vitro (ECCMID 2007)
Targanta Announces $70 Million Series C Financing
Targanta To Present at 9TH Annual BIO CEO and Investor
Conference Therapeutic Workshop
Comparative Efficacy of Rifabutin and Gatifloxacin in the
Rat Osteomyelitis Model
Efficacy of Oritavancin in a Murine Model of Bacillus
anthracis Spore Inhalation Anthrax
Effect of Polysorbate 80 on Oritavancin Binding...
Influence of Polysorbate-80 on Susceptibility of Gram-positive
Bacteria to Oritavancin
Efficacy of Oritavancin in a mouse model of S. pneumoniae...